AR
CERE

Advisory Research’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Advisory Research’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,824
Closed -$604K – 412
2022
Q2 		$604K Sell
22,824
-20,767
-48% -$590K 0.06% 204
2022
Q1 		$1.53M Buy
+43,591
New +$1.27M 0.12% 134

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Advisory Research's CERE Position: Q3 2022 in Review

Advisory Research sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2022, closing a stake of 22,824 shares — an estimated $604K sold.

Advisory Research first reported a position in CERE in Q1 2022 and held it in 2 quarters. The position peaked at $1.53M in Q1 2022. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

  • Advisory Research reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Advisory Research sold 22,824 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $604K.
  • Advisory Research first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Advisory Research's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.53M in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Advisory Research's 13F filing for Q3 2022, filed 15 Nov 2022.